Siglec-6 is a Target for Chimeric Antigen Receptor T-cell Treatment of Chronic Lymphocytic Leukemia

por Kovalovsky, Damian, Yoon, Jeong Heon, Cyr, Matthew G., Simon, Samantha, Voynova, Elisaveta, Rader, Christoph, Wiestner, Adrian, Alejo, Julie, Pittaluga, Stefania, Gress, Ronald E.
Publicado 2021

Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

por Cyr, Matthew G, Mhibik, Maissa, Qi, Junpeng, Peng, Haiyong, Chang, Jing, Gaglione, Erika M, Eik, David, Herrick, John, Venables, Thomas, Novick, Scott J, Courouble, Valentine V, Griffin, Patrick R, Wiestner, Adrian, Rader, Christoph
Publicado 2022

A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase

por Martinez, Natalia J., Asawa, Rosita R., Cyr, Matthew G., Zakharov, Alexey, Urban, Daniel J., Roth, Jacob S., Wallgren, Eric, Klumpp-Thomas, Carleen, Coussens, Nathan P., Rai, Ganesha, Yang, Shyh-Ming, Hall, Matthew D., Marugan, Juan J., Simeonov, Anton, Henderson, Mark J.
Publicado 2018